Form D · Pharmaceuticals

Gilgamesh Pharma Inc.

New York, NY · CIK 0002107396

Offering snapshot reported Mar 31, 2026 · SEC filing

Reported sold
$2.25M
Offering amount: $15M
Investors reported
3
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Mar 27, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 31, 2026Initial$2,250,000No comparison3SEC filing
Mar 24, 2026Initial$60,000,000No comparison40SEC filing
Feb 4, 2026InitialYet to sellNo comparison8SEC filing
Feb 4, 2026Initial$6,090,946No comparison9SEC filing

Offering details

Securities
Option to acquire, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-578605
Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.

Source: Form D, filed Mar 31, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Berman Director
Zia Huque Director
Andrew Kruegel Director, Executive
Amy Kruse Director
Phil Skolnick Director
Jonathan Sporn Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
113 University Place, Suite 1019
New York, NY, 10003
Phone: 929-723-4861